ALBI Grade Is a Predictive Factor of Lenvatinib Treatment Discontinuation due to Adverse Events in Hepatocellular Carcinoma

D Enomoto, K Yamamoto, Y Matsumoto… - Anticancer …, 2023 - ar.iiarjournals.org
Background/Aim: Lenvatinib is a multiple-tyrosine kinase inhibitor used to treat
hepatocellular carcinoma (HCC), and its systematic concentration varies according to liver …

[HTML][HTML] Impact of baseline ALBI grade on the outcomes of hepatocellular carcinoma patients treated with lenvatinib: a multicenter study

K Ueshima, N Nishida, S Hagiwara, T Aoki, T Minami… - Cancers, 2019 - mdpi.com
Background: This study investigated the impact of baseline liver function according to the
Child–Pugh score and ALBI (albumin-bilirubin) grade on the outcomes of patients with …

Exploratory analysis of target concentration of lenvatinib in the treatment of hepatocellular carcinoma

S Noda, H Iida, T Fujimoto, Y Wakasugi… - Cancer chemotherapy …, 2021 - Springer
Purpose We aimed to evaluate exposure–toxicity/efficacy relationship of lenvatinib by
determining its target trough concentration for patients with hepatocellular carcinoma (HCC) …

Analyses of objective response rate, progression‐free survival, and adverse events in hepatocellular carcinoma patients treated with lenvatinib: a multicenter …

T Hatanaka, S Kakizaki, T Nagashima… - Hepatology …, 2020 - Wiley Online Library
Aim The aim of this study was to investigate the predictive factors of objective response rate
(ORR) and progression‐free survival (PFS), and the correlation of albumin‐bilirubin (ALBI) …

Early relative change in hepatic function with lenvatinib for unresectable hepatocellular carcinoma

A Hiraoka, T Kumada, M Atsukawa, M Hirooka, K Tsuji… - Oncology, 2019 - karger.com
Background/Aim: Lenvatinib (LEN) has been developed for the treatment of unresectable
hepatocellular carcinoma (u-HCC). We aimed to elucidate the relative change in hepatic …

Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib

IG Rapposelli, T Tada, S Shimose, V Burgio… - Liver …, 2021 - Wiley Online Library
Abstract Background and Aim Lenvatinib is a standard of care option in first‐line therapy of
advanced hepatocellular carcinoma (HCC). In the present study, we aim to identify, in …

[HTML][HTML] Early predictors of objective response in patients with hepatocellular carcinoma undergoing lenvatinib treatment

I Saeki, T Yamasaki, S Yamashita, T Hanazono… - Cancers, 2020 - mdpi.com
There are limited reports regarding early predictors of objective response (OR) in patients
with hepatocellular carcinoma (HCC) treated with lenvatinib. This retrospective study …

Impact of relative dose intensity of early-phase lenvatinib treatment on therapeutic response in hepatocellular carcinoma

AYA Takahashi, M Moriguchi, Y Seko… - Anticancer …, 2019 - ar.iiarjournals.org
Background: Factors associated with response to lenvatinib have not been clarified in
patients with hepatocellular carcinoma (HCC). Patients and Methods: This study …

Association of lenvatinib plasma concentration with clinical efficacy and adverse events in patients with hepatocellular carcinoma

K Hata, K Suetsugu, N Egashira, Y Makihara… - Cancer chemotherapy …, 2020 - Springer
Purpose This study aimed to examine the association between the trough plasma
concentration of lenvatinib with the objective response rate (ORR) and adverse events in …

[HTML][HTML] Liver function changes in patients with hepatocellular carcinoma treated with lenvatinib: predictive factors of progression to Child-Pugh class B, the formation …

T Hatanaka, S Kakizaki, T Nagashima, M Namikawa… - Cancers, 2020 - mdpi.com
Simple Summary Many drugs has become available for the advanced hepatocellular
carcinoma and sequential systemic therapies play an important role in the clinical settings …